Qinggang Wang, PhD

Bristol-Myers Squibb
Director of Chemical Process Development
Qinggang Wang, Ph.D., is currently a scientific director in Chemical Process Development in Bristol-Myers Squibb Company. His work has been focused on CMC analytical supports for various projects within BMS portfolio, including small molecules, synthetic peptides and oligonucleotides. Qinggang is a member of ISPE PQLI Q2/Q14 team and Analytical Leadership Group of IQ Consortium.

Related Articles

Readiness for Implementation of ICH Q2(R2) and Q14 Industry Survey Results
Features
Readiness for Implementation of ICH Q2(R2) and Q14 Industry Survey Results

The International Council for Harmonisation (ICH) Q2(R2) and Q14 guidelines, finalized in late 2023, outline strategies for analytical procedure development, validation, and lifecycle management. As global implementation progresses, ISPE’s PQLI® Analytical Method Strategy Team surveyed industry stakeholders in mid-2024 to assess readiness, identify opportunities, and highlight areas...